The Ras/Raf/MEK/extracellular signal regulated kinase (ERK) (Ras/mitogen-activated protein kinases (MAPK)) signal transduction pathway is a crucial mediator of many fundamental biological processes, including cellular proliferation, survival, angiogenesis and migration. Aberrant signalling through the Ras/MAPK cascade is common in a wide array of malignancies, including multiple myeloma (MM), making it an appealing candidate for the development of novel targeted therapies. In this review, we explore our current understanding of the Ras/MAPK pathway and its role in MM. Additionally, we summarise the current status of small molecule inhibitors of MEK under clinical evaluation, and discuss future approaches required to optimise their use.? 2013 Macmillan Publishers Limited All rights reserved.
Leow, C. C-Y., Gerondakis, S. D., & Spencer, A. (2013). MEK inhibitors as a chemotherapeutic intervention in multiple myeloma. Blood Cancer Journal, 3, 1 - 8. [e105]. https://doi.org/10.1038/bcj.2013.1